The global GLP-1 Receptor Agonist Market is estimated to be valued at US$ 14319.85 Mn in 2023 and is expected to exhibit a CAGR of 6.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.Market Overview: GLP-1 receptor agonists are injectable drug products used for the treatment of type 2 diabetes. They work by stimulating the release of...
Introduction to GLP-1 Receptor AgonistsGlucagon-like peptide-1 (GLP-1) receptor agonists are a class of anti-diabetic medications used to treat type 2 diabetes. They work by mimicking the effects of GLP-1, a hormone released after eating that stimulates insulin secretion and suppresses glucagon secretion. The major GLP-1 receptor agonists approved for medical use include exenatide, liraglutide,...
GLP-1 receptor agonists, commonly referred to as GLP-1 RAs, mimic the body's own incretin hormone called glucagon-like peptide-1 (GLP-1). GLP-1 plays an important role in regulating blood sugar levels after eating by stimulating insulin secretion from pancreatic beta cells and suppressing glucagon release from alpha cells. However, GLP-1 is only active for a short time as it is quickly broken...
The Hypoglycemic Drugs Market plays a crucial role in diabetes management, catering to the needs of millions of individuals affected by diabetes worldwide. Diabetes is a chronic metabolic disorder characterized by high blood glucose levels, which can lead to severe complications if not adequately controlled. Hypoglycemic drugs are medications designed to lower blood glucose levels and improve...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Romaian